India, May 27 -- Zealand Pharma A/S (ZEAL.CO), a biotechnology company focused on advancing medicines for obesity and metabolic health, on Wednesday reported it will present its data from the obesity and metabolic health pipeline at the 2026 scientific sessions of the American Diabetes Association (ADA), held between June 5 and June 8, 2026, in New Orleans, Louisiana.
The data to be presented include Phase 2 results from the ZUPREME-1 trial of Petrelintide for the treatment of obesity.
Petrelintide is an investigational long-acting amylin analogue designed for chemical and physical stability, suitable for once-weekly subcutaneous administration.
ZUPREME-1 is a Phase 2 randomised, double-blind, placebo-controlled, parallel-group, multinat...